Adagene logo

AdageneNASDAQ: ADAG

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

China

IPO:

09 February 2021

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$97.84 M
-77%vs. 3y high
45%vs. sector
-vs. 3y high
-vs. sector
-36%vs. 3y high
52%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 5 min ago
$2.21-$0.01(-0.45%)

Dividend

No data over the past 3 years
No data over the past 3 years
No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ADAG Latest News

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
zacks.com20 November 2024 Sentiment: -

Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Adagene (ADAG) This Year?
zacks.com11 September 2024 Sentiment: NEUTRAL

Here is how Adagene Inc. Sponsored ADR (ADAG) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
globenewswire.com12 July 2024 Sentiment: POSITIVE

SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024.

Adagene to Present at Investor Conferences in June
globenewswire.com22 May 2024 Sentiment: POSITIVE

SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024.

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
GlobeNewsWire04 January 2024 Sentiment: POSITIVE

- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this proven immunotherapy target -

Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
Zacks Investment Research27 September 2023 Sentiment: POSITIVE

Here is how Adagene Inc. Sponsored ADR (ADAG) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Adagene (ADAG) This Year?
Zacks Investment Research07 September 2023 Sentiment: NEUTRAL

Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research25 May 2023 Sentiment: POSITIVE

Here is how Adagene Inc. Sponsored ADR (ADAG) and The Cooper Companies (COO) have performed compared to their sector so far this year.

What type of business is Adagene?

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

What sector is Adagene in?

Adagene is in the Healthcare sector

What industry is Adagene in?

Adagene is in the Biotechnology industry

What country is Adagene from?

Adagene is headquartered in China

When did Adagene go public?

Adagene initial public offering (IPO) was on 09 February 2021

What is Adagene website?

https://www.adagene.com

Is Adagene in the S&P 500?

No, Adagene is not included in the S&P 500 index

Is Adagene in the NASDAQ 100?

No, Adagene is not included in the NASDAQ 100 index

Is Adagene in the Dow Jones?

No, Adagene is not included in the Dow Jones index

When was Adagene the previous earnings report?

No data

When does Adagene earnings report?

The next expected earnings date for Adagene is 28 March 2025